New Product Approvals, page-56

Yeah ! I am with you Biggsy and Charts.
I clarified $295m being paid upon sales target
being achieved.
Seriously I did the Math very accurately at the
time .
Sure it appears fantastic as it is meant to.
my Concern is Mayne Pharma having the
Expertise to Promote, Market and sell this E4
with enough meat in the sandwich left over.
IE Net Cash Bottom Line Profit in the Kitty.
There is without doubt more E4 Products in
The Menopause Area to come.
This will be far bigger than a Contraceptive
There are some Companies who have agreements with Mithra including this area.
Will Mayne keep paying and include Shares
with forthcoming Product Agreements ???
We do not know Mithra Margin on Products
Should these deals continue Mithra could
quite easily end up owning Mayne for debt.